Abstract | BACKGROUND: DESIGN: A total of 40 patients with type 2 diabetes complicated by hyperlipidemia were recruited prospectively and consecutively. The patients were assigned randomly in equal numbers to rosuvastatin (2.5 mg/day) and colestimide (3.0 g/day) groups. Blood and urine tests were performed at the beginning of the study and after 12 weeks. RESULTS: CONCLUSION:
|
Authors | Kohzo Takebayashi, Mariko Suetsugu, Sachiko Matsumoto, Yoshimasa Aso, Toshihiko Inukai |
Journal | Southern medical journal
(South Med J)
Vol. 102
Issue 4
Pg. 361-8
(Apr 2009)
ISSN: 1541-8243 [Electronic] United States |
PMID | 19279518
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Chemokine CCL2
- Fluorobenzenes
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Imidazoles
- Peptide Fragments
- Pyrimidines
- Resins, Synthetic
- Retinol-Binding Proteins
- Sulfonamides
- colestimide
- monocyte chemoattractant protein 1 (66-77)
- Epichlorohydrin
- 8-epi-prostaglandin F2alpha
- Rosuvastatin Calcium
- C-Reactive Protein
- Dinoprost
|
Topics |
- C-Reactive Protein
(metabolism)
- Chemokine CCL2
(metabolism, urine)
- Diabetes Mellitus, Type 2
(drug therapy, urine)
- Diabetic Nephropathies
(urine)
- Dinoprost
(analogs & derivatives, metabolism)
- Enzyme-Linked Immunosorbent Assay
- Epichlorohydrin
(therapeutic use)
- Female
- Fluorobenzenes
(therapeutic use)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hyperlipidemias
(drug therapy, urine)
- Imidazoles
(therapeutic use)
- Male
- Middle Aged
- Oxidative Stress
- Peptide Fragments
(metabolism)
- Prospective Studies
- Pyrimidines
(therapeutic use)
- Resins, Synthetic
(therapeutic use)
- Retinol-Binding Proteins
(metabolism)
- Rosuvastatin Calcium
- Sulfonamides
(therapeutic use)
|